Suppr超能文献

COPD 加重患者合并糖尿病的结局:来自 ACURE 登记处的研究结果。

Outcomes associated with comorbid diabetes among patients with COPD exacerbation: findings from the ACURE registry.

机构信息

Chinese Alliance for Respiratory Diseases in Primary Care, Beijing, China.

Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, No 2, East Yinghua Road, Chaoyang District, Beijing, 100029, China.

出版信息

Respir Res. 2021 Jan 6;22(1):7. doi: 10.1186/s12931-020-01607-6.

Abstract

BACKGROUND

Diabetes is a common comorbidity among patients with exacerbation of chronic obstructive pulmonary disease (AECOPD). Diabetes has been reported to be associated with length of stay (LOS), death, and cost among AECOPD patients. However, most studies are retrospective or have small sample sizes. The association for cost has not been researched using diabetes as a main analytic factor. This study aimed to fill gaps mentioned above, to compare basic characteristics between the diabetic and non-diabetic group, and to detect associations between diabetes and clinical outcomes among patients hospitalized with AECOPD.

METHODS

A total of 5334 AECOPD patients, classified into diabetic and non-diabetic group, were included from a prospective multicenter patient registry study. Generalized linear regression and logistic regression were separately used for the association between diabetes and direct hospitalization cost and the association between diabetes and LOS.

RESULTS

Generally, diabetic patients had a more severe profile, including being older, more overweight or obese, having more former smokers, more emergency room visits in the past 12 months, and more comorbidities occurrence. Diabetic patients also had worse clinical outcomes, including higher cost and longer LOS. Additionally, the generalized linear regression indicated that the marginal mean cost difference between diabetic and non-diabetic patients was RMB (¥) 775.7.

CONCLUSIONS

AECOPD patients with comorbid diabetes had a more severe profile and higher direct hospitalization cost. Diabetes screening and integrated care programs might help reduce the heavy comorbidity and economic burden. Moreover, corticosteroids and metformin could be considered in the treatment of these patients. Trial registration Clinicaltrials.gov with the identifier NCT0265752.

摘要

背景

糖尿病是慢性阻塞性肺疾病(COPD)加重患者的常见合并症。据报道,糖尿病与 COPD 加重患者的住院时间(LOS)、死亡和费用有关。然而,大多数研究是回顾性的或样本量较小。尚未使用糖尿病作为主要分析因素来研究费用的相关性。本研究旨在填补上述空白,比较糖尿病和非糖尿病组之间的基本特征,并检测糖尿病与 COPD 加重住院患者临床结局之间的关系。

方法

从一项前瞻性多中心患者登记研究中纳入了 5334 例 COPD 加重患者,分为糖尿病和非糖尿病组。分别使用广义线性回归和逻辑回归分析糖尿病与直接住院费用之间的关系以及糖尿病与 LOS 之间的关系。

结果

一般来说,糖尿病患者的病情更严重,包括年龄较大、超重或肥胖、更多的前吸烟者、过去 12 个月内急诊就诊次数更多以及合并症发生次数更多。糖尿病患者的临床结局也更差,包括更高的费用和更长的 LOS。此外,广义线性回归表明,糖尿病和非糖尿病患者之间的边际平均费用差异为人民币(¥)775.7。

结论

患有合并糖尿病的 COPD 加重患者病情更严重,直接住院费用更高。糖尿病筛查和综合护理计划可能有助于减轻这些患者的严重合并症和经济负担。此外,皮质类固醇和二甲双胍可考虑用于这些患者的治疗。试验注册Clinicaltrials.gov 标识符为 NCT0265752。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5e20/7789818/979fb82a1998/12931_2020_1607_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验